KRAS and colorectal carcinoma: That is, several clinical studies of CRCs have reported that TP53 mutation is associated with a poor prognosis for patients treated with cetuximab.48,51–54 Another CRC study suggested that TP53 mutations are predictive for cetuximab sensitivity, especially for patients without KRAS mutations,55 and proposed that TP53 genotyping could be useful in the clinic to help select CRC patients who are likely to benefit from cetuximab-based treatment.